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Figure S2 – liver esterase activity is concentration dependent  (Sigma E3019) 
 
Figure S2 
Inhibition of 3H-CGP12177 whole cell binding in CHO-β1 cells by increasing concentrations of 
liver esterase (Sigma E3019) in the presence of fixed concentrations of a) esmolol, b) betaxolol 
and c) timolol. Bars represent total binding and non-specific binding (determined by the 
presence of 10µM propranolol) in the absence and presence of the maximum concentration of 
esterase obtainable (8.5u/ml). The fixed concentrations of esmolol, betaxolol and timolol were 
chosen to represent different points on their competition-binding curves, thus 300nM esmolol 
caused only a little inhibition of specific binding whereas 10µM inhibited most of the specific 
binding. Concentrations of esterase of 0.085u/ml and above hydrolysed esmolol such that it was 
no longer able to inhibit specific binding whereas betaxolol and timolol were not affected. 
Maximum concentrations of esterase (8.5u/ml) caused a small increase in total binding over the 
6hr incubation which may be partly responsible for the increase in binding seen in the betaxolol 
and timolol at this concentration of esterase. The concentrations of 3H-CGP12177 were a) 
1.09nM, b) 0.84nM and c) 0.84nM. Data points are mean ± s.e.mean of triplicate determinations 
and these single experiments are representative of 7 separate experiments in each case. 
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Inhibition of 3H-CGP12177 whole cell binding in CHO-β1 cells in response to increasing 
concentrations of porcine liver carboxyl esterase (Sigma E2884) in the presence of fixed 
concentrations of a) esmolol and b) betaxolol. Bars represent total binding and non-specific 
binding (determined by the presence of 10µM propranolol) in the absence and presence of the 
maximum concentration of esterase obtainable (2.8u/ml). The fixed concentrations of esmolol 
and betaxolol were chosen to represent different points on their concentration response, thus 
300nM esmolol caused only a little inhibition of specific binding whereas 10µM inhibited most 
of the specific binding.  Concentrations of esterase of 0.28u/ml and above hydrolysed esmolol 
such that it was no longer able to inhibit specific binding whereas betaxolol and timolol were not 
affected. The concentrations of 3H-CGP12177 was 1.09nM.  
                                                                 S 5 




Inhibition of 3H-CGP12177 whole cell binding in CHO-β1 cells in response to a) esmolol and b) 
betaxolol.  Cells were incubated for 2hr with 3H-CGP 12177 or for 2hr, 4hr or 6hr with ligand, 
0.28u/ml porcine liver carboxyl esterase (Sigma E2884). Bars represent total and non-specific 
binding (determined by 10µM propranolol) at each time point in the absence and presence of 
0.28u/ml esterase.  Longer incubation caused more hydrolysis of esmolol and thus increasing 
rightward shifts of the esmolol concentration response curve whereas the response to betaxolol 
were unaffected. The concentrations of 3H-CGP12177 was 1.00nM in each experiment.  
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Table S1 – affinity of ester ligand hydrolysis products 
 
 
parent Hydrolysis product CHO-β1 
Log KD 
n  CHO-β2 
Log KD  
n 
Ligands sensitive to liver esterase only 
Esmolol 31 = ASL8123 -4.06 ± 0.04 5  No binding 5 
2 32 -6.88 ± 0.06 5  -6.49 ± 0.03 5 
3 33 -6.56 ±0.08  7  -6.16 ± 0.04 5 
       
Ligands sensitive to liver and serum esterase 
10 34 -6.10 ± 0.02 4  >-4 4 
18 35  -5.27 ± 0.07 6  -5.74 ± 0.07 6 
       
Ligands with rbc esterase activity 
24, 26, 28 36 -6.47 ± 0.03 5  -5.01 ± 0.05 5 
 
Affinity (log KD values) esterase hydrolysis products. Values are mean ± s.e.mean for n separate 
experiments. Thus, the affinity (log KD) for esmolol at the β1-AR was -6.56 (Table 2), whereas 
the affinity of its hydrolysis product was very poor (-4.06). 
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Analytical Data for all novel compounds and General Experimental Chemistry Details 
 
Chemicals and solvents utilised in compound synthesis were purchased from standard suppliers 
and used without further purification. Melting points (mp) were recorded using a MP50 Melting 
point System (Mettler Toledo) and are uncorrected. High-resolution mass spectra (HRMS) time-
of-flight electrospray (TOF ES ±) were recorded on a Waters 2795 separation module/micromass 
LCT platform or a Bruker microTOFII instrument with flow injection sample introduction and 
using electrospray ionisation (ESI). 1H-NMR spectra were recorded on a Bruker-AV 400 at 
400.13 MHz. 13C-NMR spectra were recorded at 101.62 MHz. Chemical shifts (δ) are recorded 
in parts per million (ppm) with reference to the chemical shift of the deuterated solvent or an 
internal tetramethylsilane (TMS) standard. Coupling constants (J) and carbon−fluorine coupling 
constants (JCF) are recorded in Hz and the significant multiplicities described by singlet (s), 
doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), and 
doublet of triplets (dt). Liquid chromatography–mass spectrometry (LC-MS) analysis was 
performed using a Shimadzu UFLCXR chromatography system coupled to an Applied 
Biosystems API2000 mass spectrometer. Column elution was at 40 oC with a flow rate of 0.5 
mL/min using the following programme: linear gradient from 5% to 98% solvent B in solvent A 
over 2 min, followed by isocratic elution at 98% B for 2 min, where solvent A was 0.1% 
HCOOH in H2O and solvent B was 0.1% HCOOH in MeCN. Eluents were monitored using UV 
detection (λ 220 and 254 nm) and MS. The following HPLC columns were used: Phenomenex 
Gemini-NX, 3 μm particle size, 110 Å pore size, C18 stationary phase, 50 × 2mm column length 
and diameter (system 1) and Phenomenex Luna, 3 μm particle size, 110 Å pore size, 







1H NMR (DMSO-d6) : δ 0.97 (dd, J = 2.0/ 4.2 Hz , 6H), δ 1.47-1.89 (m, 9H), δ 2.62 (d, J = 4.2 
Hz, 1H), δ 2.64-2.73 (m, 2H), δ 2.74-2.83 (m, 1H), δ 3.73-3.81 (m, 2H), δ 3.82-3.88 (m, 1H), δ 
4.00 (dd, J = 7.0/ 4.6 Hz, 1H), δ 4.26 (d, J = 5.1 Hz, 2H), δ 4.28-4.38 (m, 2H), δ 4.92 (s, 1H), δ 
6.43 (dd, J = 2.9/ 5.9 Hz, 1H), δ 6.47 (d, J = 2.7 Hz, 1H), δ 6.77 (d, J = 8.6 Hz, 1H); 13C NMR 
(DMSO-d6) : δ 175.50, 153.23, 142.93, 136.42, 117.23, 108.00, 103.07, 71.28, 70.52, 68.18, 
64.67, 62.10, 49.84, 48.26, 42.86, 29.44, 25.30, 22.70. mp 70 – 71 °C; LCMS Rt: 2.26 min, 
[MH]+ 394.3, Purity 95%; HRMS (TOF ES+) C21H32NO6 [MH]
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Methyl 4-(2-(2-hydroxy-3-(o-tolyloxy)propylamino)ethoxy)benzoate (2) 
1H NMR (CDCl3) δ: 7.96-8.00 (m, 2H), 7.12-7.16 (m, 2H), 6.89-6.92 (m, 2H), 6.87 (ddd, J = 
7.5/7.5/0.9 Hz), 6.80 (d, broad, J = 8.3 Hz), 4.09-4.14 (m, 3H), 3.96-4.03 (m, 2H), 3.88 (s, 3H), 
3.08 (t, J = 5.1 Hz, 2H), 2.87-3.00 (m, 2H), 2.71 (s, broad, 2H), 2.22 (s, 3H); 13C NMR (CDCl3) 
δ: 166.90, 162.58, 156.74, 131.71, 130.84, 126.96, 126.80, 122.94, 120.90, 114.17, 111.23, 
70.53, 68.59, 67.65, 52.04, 51.97, 48.74, 16.36; mp: 92-95 °C; LCMS Rt: 2.21 min [MH]
+ 361.3, 
HRMS m/z C20H26NO5




Methyl 4-(2-(3-(2-bromophenoxy)-2-hydroxypropylamino)ethoxy)-benzoate (3) 
1H NMR (CDCl3) δ: 7.95-7.99 (m, 2H), 7.52 (dd, J = 7.9/1.5 Hz, 1H), 7.24 (ddd, J = 8.3/7.5/1.5 
Hz, 1H), 6.83-6.93 (m, 4H), 4.11-4.16 (m, 3H), 4.02-4.09 (m, 2H), 3.88 (s, 3H), 3.07-3.13 (m, 
2H), 2.94-3.03 (m, 2H), 2.87 (s, broad, 2H); 13C NMR (CDCl3) δ: 166.94, 162.60, 155.05, 
133.44, 131.74, 128.69, 122.96, 122.53, 114.22, 113.73, 112.47, 71.89, 68.25, 67.59, 52.00, 
51.75, 48.78; mp: 84-87 °C; LCMS Rt: 2.23 min [MH]
+ 424.1/426.2; HRMS m/z 
C19H23
79BrNO5




Methyl 4-(2-(3-(2-cyanophenoxy)-2-hydroxypropylamino)ethoxy)benzoate (4) 
1H NMR (CDCl3) δ: 7.92-7.97 (m, 2H), 7.46-7.53 (m, 2H), 6.99 (ddd, J = 7.6/7.6/0.8 Hz, 1H), 
6.94 (d, broad, J = 8.5 Hz, 1H), 6.87-6.91 (m, 2H), 4.02-4.16 (m, 5H), 3.86 (s, 3H), 3.08 (t, J = 
5.2 Hz), 2.89-3.05 (m, 4H); 13C NMR (CDCl3) δ: 166.89, 162.57, 160.45, 134.51, 133.73, 
131.68, 122.85, 121.28, 116.53, 114.18, 112.57, 102.15, 71.53, 67.99, 67.53, 51.94, 51.62, 
48.64; mp: 104-107 °C; LCMS Rt: 2.13 min [MH]
+ 371.3; HRMS m/z C20H23N2O5
+ [MH]+ 




Methyl 4-(2-(3-(2-cyano-5-methylphenoxy)-2-hydroxypropylamino)-ethoxy)benzoate (5) 
1H NMR (CDCl3) δ: 7.95-7.98 (m, 2H), 7.41 (d, J = 7.8 Hz, 1H), 6.90-6.93 (m, 2H), 6.82 (d, 
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2H), 2.93-3.06 (m, 2H), 2.86 (s, broad, 2H), 2.38 (s, 3H); 13C NMR (CDCl3) δ: 166.92, 162.59, 
160.46, 145.94, 133.45, 131.73, 122.96, 122.30, 116.84, 114.24, 113.40, 99.31, 71.40, 67.95, 
67.52, 51.98, 51.56, 48.71, 22.38; mp: 126-128 °C; LCMS Rt: 2.18 min [MH]
+ 385.2; HRMS 
m/z C21H25N2O5
+ [MH]+ calculated 385.1758, found 385.1771. 
 
 
Methyl 4-(2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)ethoxy)-benzoate (6) 
1H NMR (CDCl3) δ: 8.23 (d, broad, J = 8.2 Hz, 1H), 7.95-7.98 (m, 2H), 7.80 (d, broad, J = 8.0 
Hz, 1H), 7.40-7.51 (m, 3H), 8.23 (dd, J = 7.9/7.9 Hz, 1H), 6.87-6.90 (m, 2H), 6.80 (d, broad, J = 
7.6 Hz, 1H), 4.24-4.29 (m, 1H), 4.11-4.20 (m, 4H), 3.88 (s, 3H), 3.20 (s, broad, 2H), 3.09 (t, J = 
5.0 Hz, 2H), 2.94-3.07 (m, 2H); 13C NMR (CDCl3) δ: 166.93, 162.52, 154.31, 134.60, 131.71, 
127.66, 126.56, 125.91, 125.60, 125.41, 122.95, 121.83, 120.83, 114.18, 105.05, 70.64, 68.55, 
67.45, 52.07, 51.98, 48.66; mp: 83-86 °C; LCMS Rt: 2.29 min [MH]
+ 396.2; HRMS m/z 
C23H26NO5




Methyl 4-(2-(3-(9H-carbazol-4-yloxy)-2-hydroxypropylamino)ethoxy)-benzoate (7) 
1H NMR (CDCl3) δ: 9.71 (s, broad, carbazole N-H), 8.13 (d, broad, J = 7.8 Hz, 1H), 7.79-7.82 
(m, 2H), 7.29 (d, broad, J = 8.0 Hz, 1H), 7.20 (ddd, J = 8.1/7.1/1.1 Hz, 1H), 7.15 (dd, J = 8.0/8.0 
Hz, 1H), 6.99-7.03 (m, 1H), 6.94 (d, broad, J = 8.0 Hz, 1H), 6.73-6.77 (m, 2H), 6.51 (d, broad, J 
= 7.9 Hz, 1H), 4.08-4.23 (m, 3H), 4.02 (t, J = 5.2 Hz, 2H), 3.74 (s, 3H), 2.98-3.03 (m, 3H), 2.86-
2.91 (m, 1H), 2.71 (s, broad, 2H); 13C NMR (CDCl3) δ: 166.54, 162.33, 154.88, 141.18, 138.94, 
131.31, 126.17, 124.49, 122.62, 122.44, 122.11, 118.85, 113.93, 112.24, 110.06, 103.92, 100.48, 
70.19, 68.31, 67.28, 52.30, 51.62, 48.39; mp: 105-109 °C; LCMS Rt: 2.26 min [MH]
+ 435.3; 
HRMS m/z C25H27N2O5






1H NMR (CD3OD) δ: 7.51 (t, J = 2.0 Hz, 1H), 7.26 (dd, J = 2.0/1.6 Hz, 1H), 7.20-7.12 (m, 3H), 
7.06-7.05 (m, 2H), 6.93 (ddd, J = 7.3/2.0/1.6 Hz, 1H), 4.11-4.04 (m, 3H), 3.87 (s, 3H), 3.75 (s, 
2H), 3.40-3.37 (m, 2H), 2.97-2.84 (m, 4H); 13C NMR (CD3OD) δ: 168.13, 158.01, 155.01, 
154.00, 142.56, 135.38, 130.92, 122.91, 121.83, 120.70, 119.55, 117.81, 117.12, 116.97, 74.25, 
69.28, 56.21, 52.91, 52.6650.38, 39.91; LCMS Rt: 2.22 min [MH]
+ 452.2/454.2; HRMS m/z 
C21H27ClN3O6


































1H NMR (D6 DMSO) δ: 8.95 (s, 1H), 8.02 (s, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.36 (d, J = 8.6 Hz, 
1H), 7.19 (dd, J = 8.5/2.1 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 6.72 (d, J = 
8.6/2.2 Hz, 1H), 4.94 (d, J = 5.0 Hz, 1H), 4.21 (t, J = 6.2.0 Hz, 2H), 3.93 (d, J = 5.3 Hz, 2H), 3.88-
3.81 (m, 1H), 3.63 (s, 2H), 3.61 (s, 3H); 2.92 (t, J = 6.3 Hz, 2H), 2.74 (dd, J = 12.0/4.7 Hz, 1H), 
2.64 (d, J = 12.0 /6.5 Hz, 1H); LCMS Rt: 1.83 min [MH]
+ 478.1/480.2; HRMS m/z 
C21H25
79BrN3O5






1H NMR (D6 DMSO) δ: 7.66 (s, 1H), 7.66 (t, J = 2.0 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.24-7.14 
(m, 3H), 7.09 (d, J = 8.6 Hz, 1H), 6.93-6.90 (m, 1H), 6.28 (t, J = 5.4 Hz, 1H), 4.04-3.90 (m, 3H), 
3.62 (s, 2H), 3.61 (s, 3H), 3.18 (q, J = 5.9 Hz, 2H), 2.80-2.63 (m, 4H); 13C NMR (D6 DMSO) δ: 
171.51, 155.04, 152.86, 142.12, 133.05, 130.70, 130.16, 129.18, 127.60, 121.02, 120.46116.87, 
115.88, 113.80, 71.52, 67.68, 51.91, 51.68, 48.98, 38.60; LCMS Rt: 2.27 min [MH]
+ 
470.1/472.2; HRMS m/z C21H26
35Cl2N3O5






1H NMR (CD3OD) δ: 7.57 (br s, 1H), 7.22-7.17 (m, 3H), 6.98-6.93 (m, 1H), 6.88-6.84 (m, 3H), 
4.17-4.11 (m, 1H), 3.99 (d, J = 5.2 Hz, 2H), 3.67 (s, 3H), 3.60 (s, 2H), 3.06-2.90 (m, 4H); 13C 
NMR (CD3OD) δ: 173.88, 160.25, 158.28, 142.45, 137.10, 135.42, 131.00, 130.58, 123.10, 
123.08, 119.71, 117.97, 116.74, 114.20, 71.49, 68.69, 52.48, 52.45, 50.40, 49.28, 41.65, 39.47; 
LCMS Rt: 2.25min [MH]
+ 436.2; HRMS m/z C21H27
35ClN3O5







1H NMR (D6 DMSO) δ: 8.92 (br s, 1H), 8.24 (s, 1H), 7.18-7.12 (m, 4H), 6.89 (d, J = 8.5 Hz, 2H), 
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3.17 (q, J = 5.9 Hz, H), 2.79-2.63 (m, 4H); 13C NMR (D6 DMSO) δ: 171.86, 157.54, 155.71, 
151.89, 132.04, 130.32, 126.26, 119.79, 115.03, 114.38, 70.60, 67.63, 51.86, 51.57, 49.22, 39.22, 
38.79; LCMS Rt: 1.98min [MH]
+ 418.4; HRMS m/z C21H27
35ClN3O5







1H NMR (D6 DMSO)
 δ: 8.87 (s, 1H), 7.67 (t, J = 1.9 Hz, 1H), 7.24-7.15 (m, 4H), 6.91 (ddd, J = 
7.7/1.9/1.3 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 6.31 (t, J = 5.4 Hz, 1H), 3.94-3.85 (m, 3H), 3.71 (q, 
J = 7.2 Hz, 1H), 3.56 (s, 3H), 3.19 (q, J = 5.8 Hz, 2H), 2.76-2.61 (m, 4H), 1.35 (d, J = 7.2 Hz, 3H); 
13C NMR (D6 DMSO) δ: 174.50, 157.62, 155.09, 142.14, 133.07, 132.57, 130.18, 128.31120.47, 
116.87, 115.88, 114.54, 70.65, 67.78, 51.94, 51.65, 49.00, 43.49, 18.56; LCMS Rt: 2.28min [MH]
+ 
450.2/452.0; HRMS m/z C22H29
35ClN3O5




Methyl 2-(4-(2-(3-(2-cyanophenoxy)-2-hydroxypropylamino)ethoxy)phenyl)acetate  (14) 
1H NMR (CDCl3) δ: 7.47-7.54 (m, 2H), 7.14-7.17 (m, 2H), 6.95-7.01 (m, 2H), 6.83-6.86 (m, 
2H), 4.08-4.18 (m, 3H), 4.06 (t, J = 5.1 Hz, 2H), 3.66 (s, 3H), 3.54 (s, 2H), 3.04-3.06 (m, 3H,), 
2.88-3.01 (m, 3H); 13C NMR (CDCl3) δ: 172.42, 160.46, 157.92, 134.49, 133.71, 130.38, 126.37, 
121.20, 116.52, 114.68, 112.58, 102.12, 71.45, 67.93, 67.26, 52.07, 51.57, 48.78, 40.32; LCMS 
Rt: 2.14 min [M+1] 385.3; HRMS m/z C21H25N2O5






1H NMR (CDCl3) δ: 7.41 (d, 1H), 7.15-7.19 (m, 2H), 6.84-6.88 (m, 2H), 6.79-6.83 (m, 2H), 4.08-
4.13 (m, 3H), 4.06 (t, J = 5.1 Hz, 2H), 3.67 (s, 3H), 3.55 (s, 2H), 3.04-3.07 (m, 2H), 2.89-3.02 (m, 
2H), 2.63 (s, broad, 2H), 2.38 (s, 3H); 13C NMR (CDCl3) δ: 172.44, 160.50, 158.02, 145.88, 
133.44, 130.42, 126.43, 122.21, 116.83, 114.76, 113.41, 99.29, 71.42, 68.05, 67.47, 52.10, 51.54, 
48.90, 40.40, 22.37; mp: 69-72 °C; LCMS Rt: 2.22 min [MH]
+ 399.3; HRMS m/z C22H27N2O5
+ 
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Methyl 2-(4-(2-(2-hydroxy-3-(o-tolyloxy)propylamino)ethoxy)phenyl)-acetate (16) 
1H NMR (CDCl3) δ: 7.12-7.20 (m, 4H), 6.80-6.89 (m, 4H), 4.11-4.17 (m, 1H), 4.09 (t, J = 5.08 
Hz, 2H), 3.95-4.03 (m, 2H), 3.68 (s, 3H), 3.56 (s, 2H), 3.04-3.12 (m, 4H), 2.89-3.03 (m, 2H), 
2.22 (s, 3H); 13C NMR (CDCl3) δ: 172.43, 157.91, 156.77, 130.84, 130.46, 126.97, 126.86, 
126.57, 120.90, 114.76, 111.27, 70.48, 68.33, 67.15, 52.12, 51.95, 48.84, 40.39, 16.40; LCMS 
Rt: 2.23 min [MH]
+ 374.3; HRMS m/z C21H28NO5




Methyl 2-(4-(2-(3-(2-bromophenoxy)-2-hydroxypropylamino)ethoxy)-phenyl)acetate (17) 
1H NMR (CDCl3) δ: 7.52 (dd, J = 7.9/1.6 Hz, 1H), 7.24 (ddd, J = 8.2/7.5/1.6 Hz, 1H), 7.15-7.19 
(m, 2H), 6.79-6.93 (m, 4H), 4.10-4.15 (m, 1H), 4.04-4.08 (m, 4H), 3.68 (s, 3H), 3.55 (s, 2H), 3.06 
(t, J = 5.1 Hz, 2H), 2.91-3.01 (m, 4H); 13C NMR (CDCl3) δ: 172.43, 157.96, 155.05, 133.37, 
130.41, 128.63, 126.41, 12.38, 114.71, 113.65, 112.41, 71.83, 68.16, 67.34, 52.10, 51.74, 48.91, 
40.36; LCMS Rt: 2.23 min [M+1] 438.1/440.1; HRMS m/z C20H25
79BrNO5
+ [MH]+ calculated 




Methyl 2-(3-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethoxy)-phenyl)acetate (18) 
1H NMR (CDCl3) δ: 7.45-7.58 (m, 2H), 7.20-7.24 (m, 1H), 6.97-7.05 (m, 2H), 6.80-6.87 (m, 3H), 
4.16-4.21 (m, 1H), 4.10-4.13 (m, 4H), 3.68 (s, 3H), 3.59 (s, 2H), 3.10-3.13 (m, 2H), 2.96-3.10 (m, 
2H), 2.82 (s, broad, 2H); 13C NMR (CDCl3) δ: 172.05, 160.50, 158.88, 135.60, 134.55, 133.80, 
129.75, 122.12, 121.37, 116.51, 115.79, 113.35, 112.73, 102.34,71.37, 67.71, 66.87, 52.21, 51.51, 
48.79, 41.28; LCMS Rt: 2.15 min [MH]
+ 385.2; HRMS m/z C21H25N2O5
+ [MH]+ calculated 





methylphenyl)acetate  (19) 
1H NMR (D6 DMSO) δ: 8.78 (s, 1H), 7.66 (t, J = 1.9 Hz, 1H), 7.24-7.17 (m, 1H), 7.16 (ddd, J = 
8.3/1.9/1.1 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.91 (ddd, J = 7.7/2.0/1.1 Hz, 1H), 6.76 (d, J = 2.3 
Hz, 1H), 6.70 (dd, J = 8.3/2.5 Hz, 1H), 6.23 (t, J = 5.3 Hz, 1H), 4.94 (br s, 1H), 3.95-3.83 (m, 3H), 
3.59 (s, 3H), 3.58 (s, 2H), 3.16 (q, J = 5.8 Hz, 2H), 2.71-2.56 (m, 4H), 2.17 (s, 3H); 13C NMR 
(CDCl3) δ: 171.73, 157.64, 154.99, 142.14, 137.90, 133.06, 131.16, 130.17, 125.14, 120.44, 
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2.27 min [MH]+ 450.2/452.0; HRMS m/z C22H29
35ClN3O5






1H NMR (D6 DMSO) δ: 8.79 (s, 1H), 7.67 (t, J = 2.0 Hz, 1H), 7.21 (d, J = 7.8 Hz, 1H), 7.18 (dd, J 
= 1.9/1.3 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 7.6/2.1/1.3 Hz, 1H), 6.88 (d, J = 8.6 Hz, 
1H), 6.24 (t, J = 5.4 Hz, 1H), 3.95-3.84 (m, 3H), 3.59 (s, 3H), 3.58 (s, 2H), 3.17 (app q, J = 5.8 
Hz, 2H), 2.72-2.57 (m, 4H); 13C NMR (D6 DMSO) δ: 171.85, 157.60, 155.02, 142.15, 133.07, 
130.30, 130.17, 126.20, 120.45, 116.87, 115.87, 114.37, 70.73, 68.06, 52.16, 51.56, 49.11, 39.22, 
39.15. LCMS Rt: 2.24 min [MH]
+ 436.2/438.2; HRMS m/z C21H29
35ClN3O5
+ [MH]+ calculated 




Methyl 2-(4-(2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)ethoxy)-phenyl)acetate (21) 
1H NMR (CDCl3) δ: 8.24-8.26 (m, 1H), 7.78-7.82 (m, 1H), 7.41-7.50 (m, 3H), 7.34 (dd, J = 7.9/7.9 
Hz, 1H), 7.13-7.17 (m, 2H), 6.82-6.86 (m, 2H), 6.77 (dd, J = 7.6/0.7 Hz, 1H), 4.27-4.33 (m, 1H), 
4.10-4.19 (m, 2H), 4.07-4.09 (t, J = 5.1 Hz, 2H), 3.75 (s, broad, 2H), 3.68 (s, 3H, CH3), 3.54 (s, 
2H, CH2-C=O), 3.06-3.11 (m, 3H, N-CH2-CH2, N-CH2-CH-OH), 2.96-3.01 (m, 1H); 
13C NMR 
(CDCl3) δ: 172.40, 157.75, 154.28, 134.53, 130.40, 127.57, 126.51, 125.89, 125.55, 125.36, 
121.90, 120.69, 114.68, 104.99, 70.53, 68.14, 66.82, 52.06, 52.01, 48.66, 40.28; LCMS Rt: 2.29 
min [MH]+ 410.3; HRMS m/z C24H28NO5




Methyl 2-(4-(2-(3-(9H-carbazol-4-yloxy)-2-hydroxypropylamino)ethoxy)-phenyl)acetate (22) 
1H NMR (CDCl3) δ: 8.26 (d, broad, J = 7.8 Hz, 1H), 8.19 (s, broad, 1H), 7.34-7.40 (m, 2H), 7.30 
(dd, J = 8.0/8.0 Hz, 1H), 7.19-7.23 (m, 1H), 7.13-7.17 (m, 2H), 7.04 (dd, J = 8.1/0.5 Hz, 1H), 6.79-
6.83 (m, 2H), 6.66 (d, broad, J = 8.0 Hz, 1H), 4.20-4.34 (m, 3H), 4.05 (t, J = 5.1 Hz, 2H), 3.69 (s, 
3H,), 3.55 (s, 2H), 2.98-3.13 (m, 4H), 2.93 (s, broad, 2H); 13C NMR (CDCl3) δ: 172.55, 157.94, 
155.19, 141.11, 138.89, 130.43, 126.78, 126.46, 125.14, 123.01, 122.60, 119.81, 114.75, 112.83, 
110.20, 104.07, 101.38, 70.40, 68.58, 67.22, 52.14, 52.07, 48.88, 40.40; mp: 120-123 °C; LCMS 
Rt: 2.27 min [MH]
+ 449.2; HRMS m/z C26H29N2O5
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Methyl 2-(3-(2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethoxy)-phenyl)acetate (23) 
1H NMR (CDCl3) δ: 8.23-8.26 (m, 1H), 7.79-7.81 (m, 1H), 7.42-7.50 (m, 3H), 7.36 (dd, J = 7.8/7.8 
Hz, 1H), 7.22 (dd, J = 7.8/7.8 Hz, 1H), 6.80-6.87 (m, 4H), 4.38-4.42 (m, 1H), 4.13-4.28 (m, 3H), 
4.10 (t, J = 5.1 Hz, 2H), 3.68 (s, 3H), 3.57-3.58 (m, 2H), 3.05-3.10 (m, 3H), 2.95-3.00 (m, 1H), 
2.84 (s, broad, 2H); 13C NMR (CDCl3) δ: 172.01, 158.97, 154.42, 135.56, 134.61, 129.72, 127.62, 
126.55, 125.94, 125.66, 125.40, 122.04, 121.95, 120.76, 115.74, 113.29, 105.07, 70.67, 68.49, 
67.29, 52.18, 52.06, 48.90, 41.26; LCMS Rt: 2.32 min [MH]
+ 410.2; HRMS m/z C24H28NO5
+ 





dihydrobenzo[b][1,4]dioxin-2-yl)methyl cyclopropanecarboxylate (24) 
1H NMR (DMSO-d6) : δ 0.82-0.95 (m, 4H), δ 1.64-1.72 (m, 1H), δ 1.92 (s, 1H), δ 2.59-2.75 (m, 
2H), δ 2.92 (t, J = 5.4 Hz, 2H), δ 3.74-3.89 (m, 3H), δ 4.00 (dd, J = 7.0/4.3 Hz, 1H), δ 4.09 (t, J 
5.5 Hz, 2H), δ 4.17-4.40 (m, 6H), δ 4.97 (d, J = 4.97 Hz, 1H), δ 6.40-6.49 (m, 2H), δ 6.79 (d, J = 
8.8 Hz, 1H), δ 7.00 (d, J = 8.1 Hz, 1H), δ 7.11 (s, 1H), δ 7.54 (d, J = 8.5 Hz, 1H), δ 8.29 (s, 1H); 
13C NMR (DMSO-d6) : δ 173.86, 169.89, 161.54, 153.25, 146.48, 142.95, 136.41, 125.10, 124.03, 
117.29, 115.13, 108.62, 107.99, 103.09, 71.20, 70.52, 68.23, 68.05, 64.67, 62.45, 52.37, 48.25, 
44.75, 12.35, 8.41, 8.39; mp 166 – 168 °C, LCMS Rt: 2.12 min [MH]
+ 499.3; HRMS (TOF ES+) 
m/z C26H31N2O8 [MH]





dihydrobenzo[b][1,4]dioxin-2-yl)methyl acetate (25) 
1H NMR (DMSO-d6) : δ 0.82-0.96 (m, 3H), δ 1.64-1.72 (m, 1H), δ 1.92 (s, 1H), δ 2.59-2.76 (m, 
2H), δ 2.85-3.00 (m, 2H), δ 3.73-3.92 (m, 3H), δ 4.01 (dd, J = 7.0/ 4.3 Hz, 1H), δ 4.09 (t,  J = 5.4 
Hz, 2H), δ 4.19-4.42 (m, 5H), δ 4.97 (d, J = 4.6 Hz, 1H), δ 6.43 (dd, J = 2.8/ 5.9 Hz, 1H), δ 6.47 
(d, J = 2.8 Hz, 1H), δ 6.79 (d, J = 8.7 Hz, 1H), δ 7.01 (dd, J = 2.1/ 6.2 Hz, 1H), δ 7.11 (s, 1H), δ 
7.55 (d, J = 8.4 Hz, 1H), δ 8.29 (s, 1H); 13C NMR (DMSO-d6) : δ 170.21, 167.40, 160.95, 
153.23, 142.95, 136.40, 129.34, 126.47, 117.29, 113.85, 107.98, 103.08, 71.19, 70.50, 68.18, 
67.72, 64.66, 62.21, 52.37, 48.25, 20.55; mp 133 – 135 °C, LCMS Rt: 1.99 min [MH]
+ 461.2; 
HRMS (TOF ES+) m/z C23H29N2O8 [MH]
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(6-(2-Hydroxy-3-((2-((1-oxoisoindolin-5-yl)oxy)ethyl)amino)propoxy)-2,3-
dihydrobenzo[b][1,4]dioxin-2-yl)methyl acetate (26) 
1H NMR (DMSO-d6) : δ 1.23 (s, 1H), δ 2.06 (s, 3H), δ 2.62-2.83 (m, 2H), δ 2.98 (t, J = 5.3 Hz, 
2H), δ 3.73-3.91 (m, 3H), δ 4.00 (dd, J = 7.2/ 4.2 Hz, 1H), δ 4.12 (t, J = 5.1 Hz, 2H), δ 4.18-4.26 
(m, 2H), δ 4.27-4.39 (m, 4H), δ 5.08 (s, 1H), δ 6.43 (dd, J = 2.8/ 5.9 Hz, 1H), δ 6.48 (d, J = 2.8 
Hz, 1H), δ 6.79 (d, J = 8.9 Hz, 1H), δ 7.01 (dd, J = 2.1/ 6.2 Hz, 1H), δ 7.11 (s, 1H), δ 7.55 (d, J = 
8.4 Hz, 1H), δ 8.30 (s, 1H); mp 159 -160 °C; LCMS Rt: 2.04 min [MH]
+ 473.2; HRMS (TOF 
ES+) m/z C23H29N2O8 [MH]





dihydrobenzo[b][1,4]dioxin-2-yl)methyl cyclopentanecarboxylate (27) 
1H NMR (DMSO-d6) : δ 1.49-1.89 (m, 9H), δ 2.32-2.34 (m, 1H), δ 2.59-2.74 (m, 3H), δ 2.76-
2.82 (m, 1H), δ 2.91 (t, J = 5.7 Hz, 2H), δ 3.76-3.89 (m, 3H), δ 4.00 (dd, J = 7.0/ 4.5 Hz, 1H), δ 
4.07 (t, J = 5.5 Hz, 2H), δ 4.24-4.38 (m, 4H), δ 4.98 (d, J = 4.1 Hz, 1H), δ 6.43 (dd, J = 2.8/ 6.0 
Hz, 1H), δ 6.48 (d, J = 2.8 Hz, 1H), δ 6.77 (d, J = 8.9 Hz, 1H), δ 6.97 (d, J = 8.8 Hz, 2H), δ 7.83 
(d, J = 9.0 Hz, 2H); 13C NMR (DMSO-d6) : δ 175.52, 167.38, 160.94, 153.21, 142.94, 136.44, 
129.33, 126.47, 117.24, 113.84, 107.98, 103.08, 71.19, 70.52, 68.17, 67.71, 64.67, 62.11, 52.36, 
48.24, 42.86, 29.45, 25.31; mp 145 – 146 °C; LCMS Rt: 2.25 min [MH]
+ 515.2; HRMS (TOF 
ES+) m/z C27H35N2O8 [MH]





dihydrobenzo[b][1,4]dioxin-2-yl)methyl cyclopentanecarboxylate (28) 
1H NMR (DMSO-d6) : δ 1.47-1.89 (m, 9H), δ 2.59-2.84 (m, 4H), δ 2.92 (t, J = 5.4 Hz, 2H), δ 
3.75-3.88 (m, 3H), δ 3.99 (dd, J = 7.1/ 4.5 Hz, 1H), δ 4.09 (t, J = 5.5 Hz, 2H), δ 4.23-4.34 (m, 
5H), δ 4.97 (d, J = 4.6 Hz, 1H), δ 6.43 (dd, J = 2.8/ 5.8 Hz, 1H), δ 6.47 (d, J = 2.8 Hz, 1H), δ 
6.77 (d, J = 8.8 Hz, 1H), δ 7.00 (dd, J = 2.1/ 6.1 Hz, 1H), δ 7.11 (s, 1H), δ 7.55 (d, J = 8.0 Hz, 
1H), δ 8.29 (s, 1H); 13C NMR (DMSO-d6) : δ 175.52, 169.85, 161.53, 153.22, 146.47, 142.94, 
136.44, 125.10, 124.01, 117.24, 115.12, 108.62, 107.98, 103.07, 71.19, 70.53, 68.20, 68.03, 
64.67, 62.11, 52.36, 48.24, 44.73, 42.86, 29.45, 25.31; mp 171 – 174 °C; LCMS Rt: 2.24 min 
[MH]+ 527.2; HRMS (TOF ES+) C28H35N2O8 [MH]







































1H NMR (D6 DMSO) δ: 8.78 (s, 1H), 7.65 (t, J = 1.9 Hz, 1H), 7.62 (t, J = 1.0 Hz, 1H), 7.61 (d, J 
= 9.4 Hz, 1H), 7.26 (d, J = 2.5 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.16 (ddd, J = 7.8/1.8/1.2 Hz, 
1H), 7.13 (d, J = 9.0/2.6 Hz, 1H), 6.91 (ddd, J = 7.7/2.0/1.1 Hz, 1H), 6.24 (t, J = 5.4 Hz, 1H), 
5.01 (br s, 1H), 4.35 (q, J = 7.1 Hz, 2H), 4.04-3.99 (m, 1H), 3.95-3.90 (m, 2H), 3.17 (q, J = 5.8 
Hz, 2H), 2.74-2.61 (m, 4H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (D6 DMSO) δ: 158.61, 155.58, 
155.01, 150.03, 145.63, 142.13, 133.06, 130.16, 127.22, 120.45, 117.98, 116.84, 115.85, 114.12, 
112.79, 105.09, 71.46, 68.10, 61.10, 52.11, 49.11, 14.11; LCMS Rt: 2.32 min [MH]
+ 
476.1/478.0; HRMS (TOF ES+) m/z C23H27
35ClN3O6 [MH]







1H NMR (DMSO-d6) : δ 0.98 (dd, J = 1.3/ 3.1 Hz, 6H), δ 2.05 (s, 3H), δ 2.61-2.72 (m, 2H), δ 
3.73-3.83 (m, 3H), δ 3.85 (dd, J = 2.7/ 6.4 Hz, 1H), δ 4.00 (dd, J = 7.2/ 6.1 Hz, 1H), δ 4.20-4.30 
(m, 2H), δ 4.30 (dd, J = 1.3/ 5.8 Hz, 2H), δ 4.98 (s, 1H), δ 6.43 (dd, J = 2.9/ 4.1 Hz, 1H), δ 6.48 
(d, J = 2.7 Hz, 1H), δ 6.79 (d, J = 8.9 Hz, 1H). LCMS Rt: 1.97 min [MH]
+ 340.2; HRMS (TOF 




3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoic acid (31 = ASL8123) 




4-(2-((2-Hydroxy-3-(o-tolyloxy)propyl)amino)ethoxy)benzoic acid (32) 
1H (400 MHz, MeOH-d4) δ 7.99 (d, J 8.9 Hz, 2H), 7.17-7.03 (m, 4H), 6.89 (d, J 8.1 Hz, 1H), 
6.84 (at, J 7.4 Hz, 1H), 4.42 (t, J 5.2 Hz, 3H), 4.42-4.33 (m, 1H), 4.09 (dd, J 9.9, 4.8 Hz, 1H), 
4.01 (dd, J 9.9, 5.7 Hz, 1H), 3.61 (t, J 5.0 Hz, 2H), 3.48 (dd, J 12.8, 3.0 Hz, 1H), 3.29 (d, J 2.7 
Hz, 1H), 2.18 (s, 3H); 13C (100 MHz, MeOH-d4) δ 169.5, 163.0, 157.8, 132.9, 132.6, 131.6, 
128.0, 127.7, 122.0, 115.4, 112.4, 71.0, 66.6, 64.5, 51.6, 48.0, 16.4; Mp 211-213 C; HRMS 
(ESI+): m/z calcd for C19H24NO5 [M+H]

































                                                                 S 17 
 
4-(2-((3-(2-Bromophenoxy)-2-hydroxypropyl)amino)ethoxy)benzoic acid (33) 
1H (400 MHz, DMSO-d6) δ 12.66 (bs, 1H), 9.46 (bs, 2H), 7.91 (d, J = 8.8 Hz, 2H), 7.56 (dd, J = 
7.9, 1.5 Hz, 1H), 7.40-7.26 (m, 1H), 7.15 (dd, J = 8.3, 1.1 Hz, 1H), 7.07 (d, J = 8.9 Hz, 2H), 6.90 
(td, J = 7.8, 1.3 Hz, 1H), 6.02 (bs, 1H), 4.42 (t, J = 5.2 Hz, 2H), 4.39-4.29 (m, 2H), 4.13 (dd, J = 
10.1, 4.7 Hz, 1H), 4.07 (dd, J = 10.1, 5.5 Hz, 1H), 3.44 (d, J = 10.2 Hz, 2H), 3.32 (dd, J = 12.8, 
2.8 Hz, 2H), 3.17 (dd, J = 12.7, 9.3 Hz); 13C (100 MHz, DMSO-d6) δ 166.8, 161.2, 154.5, 132.9, 
131.3, 129.0, 123.6, 122.3, 114.5, 114.0, 111.1, 70.7, 64.7, 63.5, 50.0, 46.0; mp 238-239 C (HCl 
salt); HRMS (ESI+): m/z calcd for C18H21BrNO5 [M+H]






1H NMR (300 MHz, DMSO-d6) δ: 9.25 (s, 1H), 7.67 (br s, 1H), 7.30 (d, J = 2.2 Hz, 1H), 7.21 -
7.18 (m, 2H), 7.14 (dd, J = 8.6, 2.2 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.90 (ddd, J = 6.5, 2.2, 2.2 
Hz, 1H), 6.79 (br t , J = 5.5 Hz, 1H), 3.98 (br s, 3H), 3.43 (s, 2H), 3.25 (br q, J = 5.8 Hz, 2H), 
2.87 - 2.83 (m, 1H), 2.76 - 2.71 (m, 3H); 13C NMR (DMSO-d6) δ: 173.50, 155.25, 152.37, 
142.30, 133.03, 130.63, 130.13, 129.76, 129.06, 120.88, 120.37, 116.85, 115.87, 113.70, 71.42, 
67.14, 51.52, 48.71, 40.63, 38.29; LCMS Rt: 2.01 min [MH]+ 456.1/458.1; HRMS (ESI+) calcd 
for C20H24




2-(3-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethoxy)phenyl)acetic acid (35) 
1H NMR (400 MHz, Methanol-d4) δ 7.7 – 7.6 (m, 2H), 7.2 (t, J = 8.1 Hz, 2H), 7.1 (td, J = 7.7, 
0.9 Hz, 1H), 7.0 (s, 1H), 7.0 (d, J = 7.6 Hz, 1H), 6.9 (dd, J = 8.2, 2.4 Hz, 1H), 4.4 (dq, J = 9.4, 
4.4 Hz, 1H), 4.3 (t, J = 5.0 Hz, 2H), 4.3 (dd, J = 9.9, 4.7 Hz, 1H), 4.2 (dd, J = 9.9, 5.4 Hz, 1H), 
3.6 – 3.5 (m, 4H), 3.5 (dd, J = 12.9, 3.2 Hz, 1H), 3.4 – 3.4 (m, 1H); 13C NMR (101 MHz, 
DMSO) δ 160.9, 160.8, 158.9, 135.5, 134.1, 129.5, 121.5, 121.4, 116.9, 116.1, 113.7, 113.6, 
112.6, 101.1, 71.9, 70.9, 70.1, 62.9, 52.5, 48.8.  LCMS Rt: 2.07 min [MH]
+; HRMS (ESI+) calcd 
for C20H22N2O5 [M+H





































1H (400 MHz, MeOH-d4/D2O (1:1)) δ 7.68 (1 H, d, J 8.5 Hz), 7.16 (1 H, d, J 1.7 Hz), 7.10 (1 H, 
dd, J 8.5, 2.2 Hz), 6.80 (1 H, d, J 8.8 Hz), 6.48 (1 H, dd, J 8.8, 2.9 Hz), 6.45 (1 H, d, J 2.8 Hz), 
4.42 (4 H, d, J 6.0 Hz), 4.33 (2 H, dt, J 8.5, 4.2 Hz), 4.29 (1 H, dd, J 11.5, 2.2 Hz), 4.19-4.10 (1 
H, m), 4.06-3.95 (3 H, m), 3.75 (2 H, dd, J 5.1, 1.6 Hz), 3.61 (1 H, q, J 4.2 Hz), 3.43 (1 H, dd, J 
13.0, 3.5 Hz) , 3.34 (1 H, dd, J 13.0, 8.6 Hz); 13C (125 MHz, MeOH-d4/D2O (1:1)) δ 173.8, 
162.3, 153.6, 148.0, 144.0, 138.4, 125.6, 125.5, 118.5, 116.5, 109.7, 109.2, 104.5, 74.5, 71.3, 
66.3, 66.1, 64.2, 61.3, 50.6, 47.5, 46.8; Mp 226-228 C (HCl salt); HRMS (ESI+): m/z calcd for 
C22H27N2O7 [M+H]
+: 431.1813; found: 431.1818. 
HO
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